Table 1 Baseline characteristics

Age, median (range), yr

54.5 (27–74)

Male sex, n (%)

45 (60.8)

Time since diagnosis, median (range), yr

4.0 (1–9)

ECOG performance status score, n (%)

  0

30 (40.5)

  1

32 (43.2)

  2

12 (16.2)

ISS stage, n (%)

  I

33 (44.6)

  II

14 (18.9)

  III

21 (28.4)

  Unknown

6 (8.1)

High-risk cytogenetics, n (%)

15 (35.7)^a

Extramedullary disease, n (%)

22 (29.7)

No. of prior lines of therapy, median (range)

3.0 (1–9)

Previous autologous stem cell transplantation, n (%)

18 (24.3)

Prior therapies, n (%)

  Proteasome inhibitors

54 (73.0)

    Bortezomib

53 (71.6)

    Carfilzomib

3 (4.1)

  Immunomodulatory agents

65 (87.8)

    Lenalidomide

35 (47.3)

    Pomalidomide

3 (4.1)

    Thalidomide

47 (63.5)

  Prior proteasome inhibitors + immunomodulatory agents

48 (64.9)

  Monoclonal antibodies

2 (2.7)

    Daratumumab

1 (1.4)

    Isatuximab

1 (1.4)